A virtual investor event, The JMP Securities Hematology and Oncology Forum will include three panel discussions featuring the views of key opinion leaders on some of the latest developments in the cancer arena. In addition, a panel composed of seasoned life sciences investors will conclude the event by sharing perspectives on the market environment and market opportunities today.
Tuesday, December 6th
KOL Discussion: Emerging Options in Solid Tumors
Hosted by Silvan Tuerkcan, Senior Research Analyst
Trever Bivona, MD, PhD
Professor, Hematology and Oncology, University of California, San Francisco
Dr. Trever Bivona (Professor, Hematology and Oncology, UCSF) is a board-certified medical oncologist with a PhD in cell and molecular biology. He maintains an active academic clinical practice and clinical research program while also leading a basic and translational research laboratory focused on cancer genetics and precision medicine. A major research interest is enhancing the understanding of the molecular basis of targeted cancer therapy response and resistance in lung cancer and other solid cancers. The focus of this panel will be novel early-stage approaches in solid tumors NSCLC, CRC, RCC, as well as the Ras/MAPK and PI3K/AKT/mTOR pathways and options for ICI-refractory patients.
KOL Discussion: Neoantigens and The Like
Hosted by Roy Buchanan, Senior Research Analyst
Dr. Patrick Ott, MD,
Clinical Director, Melanoma Center
Director, Clinical Sciences, Center for Immuno-Oncology
Dana-Farber Cancer Institute and Harvard Medical School
Senior Vice President Innovation and Science, CureVac N.V. (CVAC)
Klaus Orlinger, PhD
Chief Scientific Officer, HOOKIPA Pharma Inc. (HOOK)
We will host Dr. Patrick Ott, MD, PhD, Associate Professor of Medicine at Harvard Medical and Clinical Director of the Melanoma Center in Medical Oncology, and Director of Clinical Sciences in the Center for Immuno-Oncology at the Dana-Farber Cancer Institute. Dr. Ott’s lab studies personal neoantigen vaccine and other IO approaches to treat cancers including melanoma. We also have Ronald Plasterk, PhD, founder and former CEO of novel neoantigen company Frame Therapeutics (acquired by CureVac in June 2008), and Dr. Klaus Orlinger, PhD, Chief Scientific Officer of Hookipa Pharma, who is responsible for generation of the company’s therapeutic immunotherapy candidates that have demonstrated best-in-class cytotoxic T-cell responses. Ronald will discuss Frame’s approach that can greatly increase the number of neoantigens from a range of tumors (paper) and Klaus will focus on Hookipa’s recently-Roche-partnered program for KRAS neoantigen vaccines.
Wednesday, December 7th
Hosted by Reni Benjamin, Senior Research Analyst
Nirav Shah, MD, MSHP
Assistant Professor of Medicine, Medical College of Wisconsin
Dr. Nirav Shah is an Assistant Professor of Medicine and practicing oncologist at the medical college of Wisconsin. His expertise involves CAR – T cell therapy and he is currently involved in several studies from corporate sponsors including Allogene, Adicet, Juno and Precision Bio, to name a few. Our panel discussion will focus on the latest and greatest in autologous and allogeneic CAR-T development, the current unmet need in the space outside of supply, and an analysis of recently reported data, as well as key results to that could be practice changing at the upcoming 2022 ASH conference.